Lantheus Holdings Inc (NASDAQ:LNTH) insider Cesare Orlandi sold 4,057 shares of the company’s stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $18.06, for a total value of $73,269.42. Following the sale, the insider now owns 73,689 shares of the company’s stock, valued at approximately $1,330,823.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Cesare Orlandi also recently made the following trade(s):
- On Thursday, January 31st, Cesare Orlandi sold 3,060 shares of Lantheus stock. The shares were sold at an average price of $16.56, for a total value of $50,673.60.
- On Friday, November 30th, Cesare Orlandi sold 7,055 shares of Lantheus stock. The shares were sold at an average price of $18.01, for a total value of $127,060.55.
Lantheus stock opened at $17.47 on Monday. The firm has a market cap of $671.98 million, a P/E ratio of 20.80, a PEG ratio of 3.53 and a beta of 1.47. The company has a debt-to-equity ratio of 4.76, a current ratio of 3.50 and a quick ratio of 2.87. Lantheus Holdings Inc has a one year low of $12.59 and a one year high of $21.45.
A number of institutional investors have recently bought and sold shares of LNTH. PNC Financial Services Group Inc. grew its holdings in Lantheus by 51.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 575 shares during the period. Financial Gravity Companies Inc. bought a new stake in Lantheus during the fourth quarter valued at about $45,000. Campbell & CO Investment Adviser LLC bought a new stake in Lantheus during the third quarter valued at about $187,000. State of Alaska Department of Revenue grew its holdings in Lantheus by 14.0% during the fourth quarter. State of Alaska Department of Revenue now owns 12,881 shares of the medical equipment provider’s stock valued at $201,000 after purchasing an additional 1,580 shares during the period. Finally, Raymond James & Associates grew its holdings in Lantheus by 43.6% during the second quarter. Raymond James & Associates now owns 15,561 shares of the medical equipment provider’s stock valued at $226,000 after purchasing an additional 4,721 shares during the period. Institutional investors own 96.95% of the company’s stock.
A number of analysts recently commented on the company. ValuEngine upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, December 1st. Zacks Investment Research cut Lantheus from a “buy” rating to a “hold” rating in a research report on Wednesday, February 6th. Finally, BidaskClub upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, January 11th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $20.00.
COPYRIGHT VIOLATION WARNING: “Lantheus Holdings Inc (LNTH) Insider Cesare Orlandi Sells 4,057 Shares” was published by Macon Daily and is owned by of Macon Daily. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://macondaily.com/2019/02/11/lantheus-holdings-inc-lnth-insider-cesare-orlandi-sells-4057-shares.html.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.